Barrett Katz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Barrett katz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Barrett Katz Today - Breaking & Trending Today

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

- VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease , respectively -

- Subcutaneous VRDN-003. ....

United States , San Francisco , Clearside Bio , Barrett Katz , Steve Mahoney , Compensation Committee , Viridian Therapeutics Inc , Key Program Milestones , Exchange Commission , Viridian Therapeutics , Chief Executive Officer , Healthcare Conference , Investigational New Drug Application , Eye Disease Portfolio , Fcrn Portfolio , Thomas Ciulla , Chief Medical Officer , Chief Development Officer , Inducement Grant , Incentive Plan , Nasdaq Listing Rule , Private Securities Litigation Reform Act , Quarterly Report ,

Viridian Stock: Market May Be Wrong In Its Disapproval (NASDAQ:VRDN)

Viridian Stock: Market May Be Wrong In Its Disapproval (NASDAQ:VRDN)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Barrett Katz , Viridian Therapeutics Inc , Digital Eye , Viridian Therapeutics , Thyroid Eye Disease , Chief Medical Officer Barrett Katz ,

Viridian Therapeutics (VRDN) Reports Positive Data from Ongoing Phase 1/2 Trial of VRDN-001

Viridian Therapeutics (VRDN) Reports Positive Data from Ongoing Phase 1/2 Trial of VRDN-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , San Diego , Kimberly Cockerham , Barrett Katz , Matt Fearer , Todd James , Viridian Therapeutics Inc , Corporate Affairs , Drug Administration , Neither The Company , Company Quarterly Report On Form , Corporate Communications , Exchange Commission , Viridian Therapeutics , Oculoplastic Surgeon , Chief Medical Officer , Thyroid Eye Disease Pipeline , Private Securities Litigation Reform Act , Thyroid Eye Disease , Quarterly Report , Vice President ,

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

- VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg –

- Ongoing THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian’s confidence in 5-dose regimen and key stakeholder feedback on evolving TED treatment paradigm -

- THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in third quarter 2023 –

- 3 mg/kg data support low-volume subcutaneous (SC) dosing profile for Company’s SC candidates in TED -

- Viridian plans to select lead SC program candidate by year-end 2023; VRDN-001 SC IND amendment and VRDN-003 IND submitted to the FDA –

- Conference call and webcast to be held today, Monday, July 10th at 5:00 p.m. ET - ....

United States , San Diego , Barrett Katz , Kimberly Cockerham , Neither The Company , Exchange Commission , Company Quarterly Report On Form , Drug Administration , Viridian Therapeutics Inc , Viridian Therapeutics , Oculoplastic Surgeon , Chief Medical Officer , Thyroid Eye Disease Pipeline , Private Securities Litigation Reform Act , Thyroid Eye Disease , Quarterly Report ,

Viridian Therapeutics' (VRDN) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Get Rating) in a research report released on Monday, Benzinga reports. They currently have a $47.00 target price on the stock. A number of other brokerages also recently commented on VRDN. B. Riley boosted their price objective on Viridian Therapeutics […] ....

Scott Dunseth Myers , Barrett Katz , Stifel Nicolaus , Needham Company , Chartwell Investment Partners , Credit Suisse Group , Voya Investment Management , Metlife Investment Management , Viridian Therapeutics Company Profile , Viridian Therapeutics Inc , Life Insurance Co , Securities Exchange Commission , Viridian Therapeutics , Get Rating , Suisse Group , Dunseth Myers , Exchange Commission , Life Insurance , Life Investment Management , Investment Management , Investment Partners , Viridian Therapeutics Daily , Nasdaq Vrdn , Reiterated Rating , Needham Company Llc ,